Gizem Erol

Gizem Erol

Curriculum Vitae

I hold the Bachelor and Master in Pharmacy from the Ege University, Izmir (Turkey) in 2018. I have done the research of my diploma thesis during a nine-month Erasmus+ exchange programme at the Department of Drug Science and Technology at the University of Turin (Italy) in 2017. There, I performed the development of Albumin Nanoparticles to controlled release Doxorubicin in the group of Prof. Roberta Cavalli. Furthermore, I did summer-internship in Izmir International Biomedicine & Genom Institute, Izmir (Turkey) in 2016 and participated in several research activities during my undergraduate education including the departments of pharmacology, analytic chemistry and botanic at Ege University. I have been enrolled in the PhD Program of Experimental Neuroscience at the School of Medicine & Surgery of the University of Milano-Bicocca in 2019. In addition to my scientific background, I performed oral and poster presentations at various national and international congresses. 

PhD project

Glycan-coated nanoparticles as inhibitors of specific lectins, a new neuroprotective therapeutic strategy for brain injury caused by ischemia

NanoCarb ETN project. (Horizon 2020 | Marie Skłodowska-Curie Actions (No 814236))

  • Curriculum: Experimental Neuroscience
  • Supervisors
    • Dr. Marco Gobbi (Mario Negri Institute for Pharmacological Research, IT)
    • Dr. Silvia Coco( University of Milano-Bicocca)

The main aim of my project concerns the identification of glycan-coated nanoparticles capable to interact with high affinity with specific lectins of the lectin pathway of the complement system.  For this, I will evaluate the binding properties of different glycosylated nanoparticles and dendrimeric scaffolds prepared by network partners, e.g. with different geometries and bringing different carbohydrate moieties with different array densities.  These studies will include the development of innovative in vitro binding assays based on Surface Plasmon Resonance and are expected to recognize important structure-affinity relationships.  The most promising inhibitors for each lectin will be identified through an optimization loop synthesis- in vitro testing and will be then assayed in binding and functional studies in cells, in particular evaluating their neuroprotective effects in human cell models of ischemia. Eventually, in vivo studies will be carried out to assess the ability of the selected inhibitors to protect from ischemic or traumatic injury in mouse models of pathology.


  1. 14-17/09/2019 17th European Meeting on Complement in Human Disease, Madrid
  2. 14-16/10/2019 2nd Brayn Congress: Brainstorming Research Assembly for Young Neuroscientists
  3. 11/11/2019 PhD Program in Neuroscience Day, Poster Presentation 
  4. 11-14/12/2019 Nanoday 4, University of Milano-Bicocca
  5. 3-4/09/2020 NanoStem-NanoCarb Joint Training School
  6. 2-6/11/2020 NanoCarb Autumn Online Workshop (Magnetic Resonance Imaging & Nuclear Imaging Radionuclides Generation, Radiochemistry and Multimodal Imaging)
  7. 1-3/03/21 First International Stroke Immunology Conference
  8. 19-23/04/2021 NanoCarb Spring Online Workshop (Glycan Analysis Training by Ludger Ltd., Research Project Management and Career Workshop by Horions Unleashed Ltd.)
  9. 18/12/2020 NeuroMI 2020 virtual annual meeting, Video-Poster Presentation

Further Details

Orcid ID: